GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » FCF Margin %

Shire (SHPG) FCF Margin % : 16.90% (As of Sep. 2018)


View and export this data going back to 1998. Start your Free Trial

What is Shire FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Shire's Free Cash Flow for the three months ended in Sep. 2018 was $654 Mil. Shire's Revenue for the three months ended in Sep. 2018 was $3,872 Mil. Therefore, Shire's FCF Margin % for the quarter that ended in Sep. 2018 was 16.90%.

As of today, Shire's current FCF Yield % is 6.10%.

The historical rank and industry rank for Shire's FCF Margin % or its related term are showing as below:

SHPG' s FCF Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 22.48
Current: 22.48


During the past 13 years, the highest FCF Margin % of Shire was 22.48%. The lowest was 0.00%. And the median was 0.00%.

SHPG's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -148.935 vs SHPG: 22.48


Shire FCF Margin % Historical Data

The historical data trend for Shire's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire FCF Margin % Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.47 68.94 34.49 17.64 22.81

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.82 31.03 22.11 19.29 16.90

Competitive Comparison of Shire's FCF Margin %

For the Biotechnology subindustry, Shire's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shire's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shire's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Shire's FCF Margin % falls into.



Shire FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Shire's FCF Margin for the fiscal year that ended in Dec. 2017 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2017 )/Revenue (A: Dec. 2017 )
=3457.9/15160.6
=22.81 %

Shire's FCF Margin for the quarter that ended in Sep. 2018 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2018 )/Revenue (Q: Sep. 2018 )
=654.3/3871.7
=16.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shire FCF Margin % Related Terms

Thank you for viewing the detailed overview of Shire's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shire (SHPG) Business Description

Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.
Executives
James H Cavanaugh director 265 HOTHORPE LANE, VILLANOVA PA 19085

Shire (SHPG) Headlines

From GuruFocus

4 Stocks John Paulson and Paul Tudor Jones Agree On

By Sydnee Gatewood Sydnee Gatewood 09-21-2018

Takeda Closes In on Shire, But It's Not a Done Deal Yet

By John Engle John Engle 05-08-2018

Publication of Scheme Document

By Marketwired Marketwired 11-12-2018